DT-101 added to current treatment for adults with major depressive disorder
Tests DT-101 against placebo in adults with major depressive disorder taking depression medicine.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Key facts
- Where
- Allentown, Bellevue, Bellflower, Boston, Chicago, Columbus, Costa Mesa, Decatur, DeSoto, Fort Worth, Hialeah, Lafayette, Little Rock, Media, New York, Orlando, Phoenix, Seattle, Skokie, and Tampa, United StatesSee the 20 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07610473, who can take part
Where in United States
- AllentownAllentown, United StatesTaking people
- BellevueBellevue, United StatesTaking people
- BellflowerBellflower, United StatesTaking people
- BostonBoston, United StatesTaking people
- ChicagoChicago, United StatesTaking people
- ColumbusColumbus, United StatesTaking people
- Costa MesaCosta Mesa, United StatesTaking people
- DecaturDecatur, United StatesTaking people
- DeSotoDeSoto, United StatesTaking people
- Fort WorthFort Worth, United StatesTaking people
- HialeahHialeah, United StatesTaking people
- LafayetteLafayette, United StatesTaking people
- Little RockLittle Rock, United StatesTaking people
- MediaMedia, United StatesTaking people
- New YorkNew York, United StatesTaking people
- OrlandoOrlando, United StatesTaking people
- PhoenixPhoenix, United StatesTaking people
- SeattleSeattle, United StatesTaking people
- SkokieSkokie, United StatesTaking people
- TampaTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Draig Therapeutics Ltd
- Trial code
- NCT07610473
- Record updated
- 14 October 2026
- Original description
In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.Read full original descriptionShow less
A Phase 2 Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder Receiving Pharmacological Therapy for Depression
In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.
Inclusion: The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent; Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent; Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022).
Exclusion: History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening; Unstable medical condition or unstable chronic disease; History of seizure; Pregnant or breastfeeding or plans to become pregnant during the study; Significant neurological abnormality; In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.